JP5051959B2 - ストレプトコッカス抗原 - Google Patents

ストレプトコッカス抗原 Download PDF

Info

Publication number
JP5051959B2
JP5051959B2 JP2002504289A JP2002504289A JP5051959B2 JP 5051959 B2 JP5051959 B2 JP 5051959B2 JP 2002504289 A JP2002504289 A JP 2002504289A JP 2002504289 A JP2002504289 A JP 2002504289A JP 5051959 B2 JP5051959 B2 JP 5051959B2
Authority
JP
Japan
Prior art keywords
glu
lys
leu
ala
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002504289A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004501618A (ja
JP2004501618A5 (enExample
Inventor
ジョセー ハメル
カテリーヌ ウーレ
ナタリエ シャルラン
デニ マルタン
ベルナール ブロデュール
Original Assignee
アイディー バイオメディカル コーポレイション オブ ケベック
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイディー バイオメディカル コーポレイション オブ ケベック filed Critical アイディー バイオメディカル コーポレイション オブ ケベック
Publication of JP2004501618A publication Critical patent/JP2004501618A/ja
Publication of JP2004501618A5 publication Critical patent/JP2004501618A5/ja
Application granted granted Critical
Publication of JP5051959B2 publication Critical patent/JP5051959B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2002504289A 2000-06-20 2001-06-19 ストレプトコッカス抗原 Expired - Fee Related JP5051959B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21268300P 2000-06-20 2000-06-20
US60/212,683 2000-06-20
PCT/CA2001/000908 WO2001098334A2 (en) 2000-06-20 2001-06-19 Streptococcus antigens

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012117846A Division JP5889103B2 (ja) 2000-06-20 2012-05-23 ストレプトコッカス抗原

Publications (3)

Publication Number Publication Date
JP2004501618A JP2004501618A (ja) 2004-01-22
JP2004501618A5 JP2004501618A5 (enExample) 2008-08-07
JP5051959B2 true JP5051959B2 (ja) 2012-10-17

Family

ID=22792041

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002504289A Expired - Fee Related JP5051959B2 (ja) 2000-06-20 2001-06-19 ストレプトコッカス抗原
JP2012117846A Expired - Fee Related JP5889103B2 (ja) 2000-06-20 2012-05-23 ストレプトコッカス抗原

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012117846A Expired - Fee Related JP5889103B2 (ja) 2000-06-20 2012-05-23 ストレプトコッカス抗原

Country Status (18)

Country Link
EP (2) EP1303612A2 (enExample)
JP (2) JP5051959B2 (enExample)
KR (1) KR100927767B1 (enExample)
CN (2) CN101260149B (enExample)
AR (1) AR033980A1 (enExample)
AU (2) AU7038101A (enExample)
CA (1) CA2413450C (enExample)
CZ (1) CZ2003154A3 (enExample)
EA (1) EA006232B1 (enExample)
HU (1) HU228706B1 (enExample)
IL (2) IL153558A0 (enExample)
MX (1) MXPA03000103A (enExample)
NO (1) NO331103B1 (enExample)
NZ (1) NZ553554A (enExample)
PL (1) PL214229B1 (enExample)
TR (1) TR200704553T2 (enExample)
UY (1) UY26783A1 (enExample)
WO (1) WO2001098334A2 (enExample)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7128918B1 (en) 1998-12-23 2006-10-31 Id Biomedical Corporation Streptococcus antigens
US7074415B2 (en) 2000-06-20 2006-07-11 Id Biomedical Corporation Streptococcus antigens
AU2002351623A1 (en) 2001-12-20 2003-07-09 Shire Biochem Inc. Streptococcus antigens
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
PL3017827T3 (pl) 2005-12-22 2019-04-30 Glaxosmithkline Biologicals Sa Szczepionka z koniugatem polisacharydu pneumokokowego
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
CN103357003A (zh) 2006-09-07 2013-10-23 葛兰素史密丝克莱恩生物有限公司 疫苗
US20100074918A1 (en) 2007-05-02 2010-03-25 Jan Poolman Vaccine
US9610339B2 (en) 2007-06-26 2017-04-04 Glaxosmithkline Biologicals, S.A. Vaccine comprising Streptococcus pneumoniae capsular polysaccharide conjugates
AU2008280799B2 (en) * 2007-07-23 2013-07-11 Sanofi Pasteur Limited Immunogenic polypeptides and monoclonal antibodies
PL2271360T3 (pl) 2008-04-16 2016-03-31 Glaxosmithkline Biologicals Sa Szczepionka
JP5722782B2 (ja) 2008-09-26 2015-05-27 ナノバイオ コーポレーション ナノエマルジョン治療用組成物及びその使用方法
KR101450958B1 (ko) 2009-04-30 2014-10-15 콜레이 파마시티컬 그룹, 인코포레이티드 폐렴구균 백신 및 그의 용도
US8668911B2 (en) 2009-05-14 2014-03-11 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
WO2010141312A2 (en) 2009-06-01 2010-12-09 Wake Forest University Health Sciences Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
ES2670576T3 (es) 2009-09-03 2018-05-31 Pfizer Vaccines Llc Vacuna de PCSK9
GB201003920D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
KR101272351B1 (ko) 2010-04-23 2013-06-07 이화여자대학교 산학협력단 새로운 카나마이신 화합물, 카나마이신 생산 스트렙토마이세스 속 미생물 및 카나마이신의 생산 방법
WO2012131504A1 (en) 2011-03-02 2012-10-04 Pfizer Inc. Pcsk9 vaccine
BR112013029514A2 (pt) 2011-05-17 2019-09-24 Glaxosmithkline Biologicals Sa composição imunogênica, vacina, e, método de tratar ou impedir uma doença
US11708411B2 (en) 2013-12-20 2023-07-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CA2937190A1 (en) 2014-01-21 2015-07-30 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
KR20220080201A (ko) 2014-01-21 2022-06-14 화이자 인코포레이티드 접합된 캡슐 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
BR112016015835B1 (pt) 2014-01-21 2023-12-26 Pfizer Inc Processo de preparação de conjugados compreendendo polissacarídeos capsulares de streptococcus pneumoniae
ES2930318T3 (es) 2014-02-14 2022-12-09 Pfizer Conjugados glucoproteicos inmunogénicos
DK3244917T5 (da) 2015-01-15 2024-10-14 Pfizer Immunogene sammensætninger til anvendelse i pneumokokvacciner
KR102800419B1 (ko) 2015-07-21 2025-04-25 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
CA3005524C (en) 2015-11-20 2023-10-10 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
MX392525B (es) 2017-01-20 2025-03-12 Pfizer Composiciones inmunogenicas para su uso en vacunas neumococicas
KR102650073B1 (ko) 2017-01-31 2024-03-20 머크 샤프 앤드 돔 엘엘씨 스트렙토코커스 뉴모니아 혈청형 19f 유래의 협막 다당류 단백질 접합체의 제조 방법
WO2018144439A1 (en) 2017-01-31 2018-08-09 Merck Sharp & Dohme Corp. Methods for making polysaccharide-protein conjugates
AU2018225083B2 (en) 2017-02-24 2023-06-01 Merck Sharp & Dohme Llc Pneumococcal conjugate vaccine formulations
PT3678654T (pt) 2017-09-07 2024-08-05 Merck Sharp & Dohme Llc Polissacáridos pneumocócicos e sua utilização em conjugados imunogénicos de polissacárido-proteína transportadora
MX2020005779A (es) 2017-12-06 2020-10-28 Merck Sharp & Dohme Composiciones que comprenden conjugados de polisacarido de streptococcus pneumoniae con proteina y metodos de uso de estos.
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2020121159A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
KR20240169145A (ko) 2018-12-19 2024-12-02 머크 샤프 앤드 돔 엘엘씨 스트렙토코쿠스 뉴모니아에 폴리사카라이드-단백질 접합체를 포함하는 조성물 및 그의 사용 방법
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
US20220184199A1 (en) 2019-04-10 2022-06-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
MX2022001241A (es) 2019-07-31 2022-04-20 Sanofi Pasteur Inc Composiciones de conjugados neumococicos multivalentes polisacarido - proteina y metodos para usar los mismos.
MX2022005252A (es) 2019-11-01 2022-06-08 Pfizer Composiciones de escherichia coli y metodos de las mismas.
US20230085173A1 (en) 2020-02-21 2023-03-16 Pfizer Inc. Purification of saccharides
CA3173729A1 (en) 2020-02-23 2021-08-26 Pfizer Inc. Escherichia coli compositions and methods thereof
CA3199094A1 (en) 2020-10-22 2022-04-28 Pfizer Inc. Methods for purifying bacterial polysaccharides
TW202227467A (zh) 2020-10-27 2022-07-16 美商輝瑞大藥廠 大腸桿菌組合物及其方法
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
EP4240410A1 (en) 2020-11-04 2023-09-13 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
TW202245835A (zh) 2021-02-04 2022-12-01 美商默沙東有限責任公司 用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
CA3218544A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against bacterial and betacoronavirus infections
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
WO2022249107A2 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
JP7714690B2 (ja) 2021-05-28 2025-07-29 ファイザー・インク コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
MX2024008039A (es) 2022-01-13 2024-07-10 Pfizer Composiciones inmunogenicas que comprenden antigenos de sacaridos capsulares conjugados y usos de los mismos.
US20250163484A1 (en) 2022-02-25 2025-05-22 Pfizer Inc. Methods for Incorporating Azido Groups in Bacterial Capsular Polysaccharides
EP4522208A1 (en) 2022-05-11 2025-03-19 Pfizer Inc. Process for producing of vaccine formulations with preservatives
WO2024084397A1 (en) 2022-10-19 2024-04-25 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
IL321062A (en) 2022-11-22 2025-07-01 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
IL321069A (en) 2022-12-01 2025-07-01 Pfizer Pneumococcal conjugate vaccine preparations
WO2024166008A1 (en) 2023-02-10 2024-08-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AU2024246082A1 (en) 2023-03-30 2025-10-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN121057590A (zh) 2023-04-14 2025-12-02 辉瑞公司 包含缀合荚膜糖抗原的免疫原性组合物及其用途
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
TW202500153A (zh) 2023-05-18 2025-01-01 美商默沙東有限責任公司 用於肺炎鏈球菌疫苗之化合物及佐劑調配物
WO2024241172A2 (en) 2023-05-19 2024-11-28 Glaxosmithkline Biologicals Sa Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection
TW202527906A (zh) 2023-09-14 2025-07-16 美商輝瑞股份有限公司 包含經結合之肺炎鏈球菌莢膜醣抗原之佐劑化致免疫性組成物及其用途
US20250161420A1 (en) 2023-11-16 2025-05-22 Merck Sharp & Dohme Llc Peptide conjugate vaccine compositions and methods for the treatment of alzheimer's disease
WO2025133971A1 (en) 2023-12-23 2025-06-26 Pfizer Inc. Improved methods for producing bacterial capsular saccharide glycoconjugates
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025191415A1 (en) 2024-03-11 2025-09-18 Pfizer Inc. Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof
WO2025219904A1 (en) 2024-04-19 2025-10-23 Pfizer Inc. Improved methods for producing glycoconjugates by reductive amination in aprotic solvent
WO2025219908A2 (en) 2024-04-19 2025-10-23 Pfizer Inc. Media and fermentation methods for polysaccharide production in bacterial cell culture

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4425437A (en) 1979-11-05 1984-01-10 Genentech, Inc. Microbial polypeptide expression vehicle
US4431739A (en) 1979-11-05 1984-02-14 Genentech, Inc. Transformant bacterial culture capable of expressing heterologous protein
US4338397A (en) 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
CZ327897A3 (cs) * 1995-06-07 1998-02-18 Alberta Research Council Imunogenní a imunostimulační oligosacharidové kompozice, způsoby jejich přípravy a použití
WO1998018931A2 (en) * 1996-10-31 1998-05-07 Human Genome Sciences, Inc. Streptococcus pneumoniae polynucleotides and sequences
JP2001517449A (ja) * 1997-09-24 2001-10-09 リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミネソタ ストレプトコッカス・ニューモニア由来のヒト補体c3分解プロテイナーゼ
JP2002531055A (ja) * 1998-07-27 2002-09-24 マイクロビアル テクニクス リミティッド 肺炎連鎖球菌のタンパク質及び核酸分子
CA2340692A1 (en) * 1998-08-19 2000-03-02 North American Vaccine, Inc. Immunogenic .beta.-propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an n-acryloylated polysaccharide
EP1115875A1 (en) * 1998-09-24 2001-07-18 Regents Of The University Of Minnesota Human complement c3-degrading polypeptide from streptococcus pneumoniae
DK1140157T3 (da) 1998-12-21 2009-06-08 Medimmune Inc Streptococcus pneumoniae-proteiner og immunogene fragmenter til vacciner
ATE394489T1 (de) 1998-12-23 2008-05-15 Id Biomedical Corp Streptococcus antigene

Also Published As

Publication number Publication date
EP1303612A2 (en) 2003-04-23
IL153558A0 (en) 2003-07-06
CN101260149A (zh) 2008-09-10
KR20030013450A (ko) 2003-02-14
PL360413A1 (en) 2004-09-06
CA2413450A1 (en) 2001-12-27
NO20026121D0 (no) 2002-12-19
WO2001098334A2 (en) 2001-12-27
EA200201280A1 (ru) 2003-06-26
NO331103B1 (no) 2011-10-10
JP2012187110A (ja) 2012-10-04
PL214229B1 (pl) 2013-07-31
CN101260149B (zh) 2016-05-11
MXPA03000103A (es) 2003-06-19
HU228706B1 (en) 2013-05-28
AU2001270381B2 (en) 2007-05-24
EA006232B1 (ru) 2005-10-27
TR200704553T2 (tr) 2007-11-21
UY26783A1 (es) 2002-01-31
JP5889103B2 (ja) 2016-03-22
JP2004501618A (ja) 2004-01-22
CA2413450C (en) 2014-02-18
HUP0301656A3 (en) 2004-10-28
EP2281891A3 (en) 2011-08-17
KR100927767B1 (ko) 2009-11-20
AU7038101A (en) 2002-01-02
WO2001098334A3 (en) 2002-09-06
EP2281891A2 (en) 2011-02-09
CN1449446A (zh) 2003-10-15
AR033980A1 (es) 2004-01-21
CZ2003154A3 (cs) 2003-06-18
IL153558A (en) 2011-07-31
NZ553554A (en) 2008-11-28
NO20026121L (no) 2003-02-13
HUP0301656A2 (hu) 2003-08-28

Similar Documents

Publication Publication Date Title
JP5051959B2 (ja) ストレプトコッカス抗原
KR100891398B1 (ko) 신규한 스트렙토코커스 항원
US7262024B2 (en) Streptococcus antigens
KR100771148B1 (ko) 그룹 b 스트렙토코커스 항원
AU2001270381A1 (en) Streptococcus antigens
JP4718099B2 (ja) ストレプトコッカス・パイオジェンス抗原
US7074415B2 (en) Streptococcus antigens
HK1122048A (en) Streptococcus antigens
AU2007207883A1 (en) Streptococcus antigens

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20080326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080619

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080619

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110530

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110831

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20110831

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120123

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120523

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120530

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120705

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120724

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150803

Year of fee payment: 3

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110831

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees